I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced the appointment of Andrew Zhu, MD, PhD, to the Company's Scientific Advisory Board.

"We are delighted to welcome Dr. Zhu to our scientific advisory board," said Dr. Jingwu Zang, Founder and Chairman of I-Mab. "His expertise in the field of gastrointestinal cancers, particularly hepatobiliary cancers, and his influence in the international medical and research communities, would be greatly beneficial to the development of our novel programs."  

Dr. Zhu is a Professor of Medicine at Harvard Medical School, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital as well as Chief Scientific Officer of Jiahui Health and Director of Jiahui International Cancer Center (JICC) in Shanghai. His clinical and research interests have focused on developing innovative therapies for hepatobiliary cancers, identifying novel molecular markers and genetic mutations, and dissecting the molecular mechanisms of drug resistance to targeted therapy in hepatobiliary cancers. 

As an internationally recognized expert in hepatocellular carcinoma and cholangiocarcinoma, Dr. Zhu has served on the Hepatobiliary Cancer Committee of the National Comprehensive Cancer Network (NCCN), the Grants Selection Committee of the American Society of Clinical Oncology (ASCO), the Hepatobiliary Cancer Task Force of The NCI Gastrointestinal Cancer Steering Committee (GISC), the American Joint Committee on Cancer (AJCC) Hepatobiliary Task Force, the Hepatocellular Carcinoma Practice Guidelines Committee of the American Association for the Study of Liver Diseases (AASLD), and the Clinical Advisory Board of the Cholangiocarcinoma Foundation.

"I am impressed with I-Mab's innovative approach to immuno-oncology research and development. I look forward to working with the board and the company to advance science and innovation, and bring transformative medicines to patients."

Dr. Zhu joins existing SAB members Patricia LoRusso, Eric K. Rowinsky, Howard L. Weiner, Yilong Wu, Timothy A. Yap, Roy S. Herbst, Chen Dong and Jun Ma.

About I-Mab

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong, S.A.R., China in China, and Maryland and San Diego in the United States.